Exelixis
EXEL
#1696
Rank
โ‚น840.29 B
Marketcap
โ‚น2,942
Share price
0.52%
Change (1 day)
68.72%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total debt

Total debt on the balance sheet as of September 2024 : โ‚น16.42 Billion

According to Exelixis's latest financial reports the company's total debt is โ‚น16.42 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Exelixis - Total debt on balance sheet (from 2000 to 2024)

Total debt by year

Year Total debt Change
2023-12-31โ‚น15.81 B0.48%
2022-12-31โ‚น15.73 B312.36%
2021-12-31โ‚น3.81 B6.31%
2020-12-31โ‚น3.58 B4.85%
2019-12-31โ‚น3.42 B228.27%
2018-12-31โ‚น1.04 B9.35%
2017-12-31โ‚น0.95 B-92.58%
2016-12-31โ‚น12.85 B-53.73%
2015-12-31โ‚น27.77 B22.76%
2014-12-31โ‚น22.62 B5.46%
2013-12-31โ‚น21.45 B16.7%
2012-12-31โ‚น18.38 B91.44%
2011-12-31โ‚น9.60 B2.8%
2010-12-31โ‚น9.34 B152.85%
2009-12-31โ‚น3.69 B-34.69%
2008-12-31โ‚น5.65 B18.61%
2007-12-31โ‚น4.76 B-11.49%
2006-12-31โ‚น5.38 B-19.56%
2005-12-31โ‚น6.69 B4.96%
2004-12-31โ‚น6.38 B26.18%
2003-12-31โ‚น5.05 B42.65%
2002-12-31โ‚น3.54 B50.13%
2001-12-31โ‚น2.36 B238.46%
2000-12-31โ‚น0.69 B20.68%
1999-12-31โ‚น0.57 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚น1.815 T 10,953.10%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น2.150 T 12,994.04%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.221 T 19,510.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น4.342 T 26,334.21%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.102 T 30,961.74%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.020 T 18,286.18%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.627 T 34,160.07%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น0.30 B-98.17%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น3.26 B-80.11%๐Ÿ‡บ๐Ÿ‡ธ USA